Emmaus Logo.png
Emmaus Life Sciences Provides Update in Response to the Coronavirus (COVID-19) Pandemic
24 mars 2020 08h00 HE | Emmaus Life Sciences
TORRANCE, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease (SCD) treatment, announced today several steps it has taken in response...
Emmaus Logo.png
Emmaus Life Sciences Announces Equity Purchase Agreement for up to $25 Million with Lincoln Park Capital
03 mars 2020 08h00 HE | Emmaus Life Sciences
TORRANCE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease  treatment, announced today the execution of a purchase agreement for...
Emmaus Logo.png
Emmaus Life Sciences Reports Preliminary Gross Sales for the Three Months Ended December 31, 2019
05 févr. 2020 08h00 HE | Emmaus Life Sciences
-- Company Reports Highest Gross Monthly Sales of 2019 and Total Gross Sales of $7.8 Million in the Fourth Quarter -- TORRANCE, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc....
Emmaus Logo.png
Emmaus Life Sciences Reports Positive Top-Line Preliminary Results in First Patient in Diverticulosis Pilot Trial
29 janv. 2020 08h00 HE | Emmaus Life Sciences
TORRANCE, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the top-line preliminary results in the first...
Emmaus Logo.png
Emmaus Life Sciences Expresses Concerns Over Inaccuracies in Draft Report Issued by ICER (Institute for Clinical and Economic Review)
27 janv. 2020 08h00 HE | Emmaus Life Sciences
TORRANCE, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, responded today to the draft evidence report by ICER dated...
Emmaus Logo.png
Emmaus Life Sciences Announces a New Adherence Program for Its Sickle Cell Disease Patients
06 janv. 2020 08h00 HE | Emmaus Life Sciences
TORRANCE, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, is pleased to announce a new adherence program available to...
Emmaus Logo.png
Emmaus Life Sciences Announces First Purchase Order from its Partnership with taiba Healthcare
31 déc. 2019 16h01 HE | Emmaus Life Sciences
TORRANCE, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that it received the initial purchase order...
Emmaus Logo.png
Emmaus Life Sciences Announces Update of its Partnership with taiba Healthcare to Expand Patient Access for Sickle Cell Disease Treatment in the Middle East and North Africa (MENA) Region
23 déc. 2019 16h01 HE | Emmaus Life Sciences
TORRANCE, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that it expects to receive shortly the initial...
Emmaus Logo.png
Emmaus Life Sciences Reports 2019 Third Quarter Financial Results
12 nov. 2019 08h00 HE | Emmaus Life Sciences
-- Net Revenues Increased 25% Year-Over-Year,Company Opens and Expands Class of Trade with Community Hematologists and Correctional Facilities -- TORRANCE, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) --...
Emmaus Logo.png
Emmaus Life Sciences Announces Equity Investment from a Corporate Investor
29 oct. 2019 08h00 HE | Emmaus Life Sciences
Company Enters Into Common Stock Purchase Agreement with Vivozon, Inc. TORRANCE, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease...